AVNS at a glance
AVANOS MEDICAL, INC. (AVNS, SEC CIK 1606498) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on May 5, 2026, an 8-K current report on July 30, 2026 and Form 4 insider filings as recently as July 28, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), AVANOS MEDICAL, INC. (AVNS) reported revenue of $701.2 million (up 1.9% from FY2024) and a net loss of $72.9 million. Diluted EPS was -$1.57.
- As of June 30, 2026, 29 institutional investment managers tracked by SignalX reported holding AVANOS MEDICAL, INC. (AVNS) shares worth $480.1 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $701.2M
- +1.9% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 29 funds
- $480.1M · +0 vs prior quarter
- Latest 8-K
- Jul 30, 2026
- Item 1.02 · Item 1.01 · Item 2.01 · Item 3.03 · Item 7.01 · Item 5.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Mar 31, 2026
Management Discussion & Analysis
- Merger agreement announced April 13, 2026; $25.00-per-share cash consideration
- Quarterly revenue and YoY change not provided in submitted excerpt
- Profitability and segment performance figures not provided in submitted excerpt
- Cash position, operating cash flow, and capital deployment details not provided in submitted excerpt
Risk Factors
- Newly added merger risk triggered by April 13, 2026 Merger Agreement
- Regulatory and approval risk from required regulatory clearances and majority stockholder approval
- Operational disruption risk from employee attrition and customer or supplier delays during merger uncertainty
- Competitive transaction risk from no-shop restrictions limiting superior acquisition proposals
- Financial exposure from $37,500,000 termination fee under specified circumstances
AI summary of the AVNS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.02: Termination of a Material Definitive Agreement
- Legacy June 24, 2022 credit agreement fully repaid and terminated at merger closing
- Replacement Credit Agreement entered concurrently, indicating post-merger refinancing of existing debt facilities
Item 1.01: Entry into a Material Definitive Agreement
- Initial term loans mature July 27, 2033, creating long-dated debt obligations for Avanos Medical
- Term SOFR borrowing margin ranges 4.75%-5.25%, indicating elevated financing costs
Item 2.01: Completion of Acquisition or Disposition of Assets
- Merger completed, triggering full replacement of Avanos’s certificate of incorporation and bylaws
- New governing documents mirror Merger Subsidiary’s pre-closing documents, with company-name references updated
Item EX-99.1: Item EX-99.1
- AIP completed Avanos acquisition for approximately $1.272 billion, converting the company into a privately held business
- Avanos shareholders received $25.00 cash per share under the merger agreement
Item 3.03: Material Modification to Rights of Security Holders
- Item 3.03 contains no standalone rights modification; it incorporates Items 2.01, 3.01, 5.01 and 5.03
- Investor impact depends on the referenced acquisition, exchange-status, control-change and governance disclosures
Item 7.01: Regulation FD Disclosure
- Merger closing announced jointly by Avanos Medical and Parent
- Transaction completion shifts focus to integration, ownership, and post-merger financial reporting
Item 5.01: Changes in Control of Registrant
- Item 5.01 incorporates acquisition, financing, and leadership-change disclosures from Items 2.01, 2.03, and 5.02
- Control-change details require review of the referenced items for transaction structure, debt obligations, and management implications
Item 5.07: Submission of Matters to a Vote of Security Holders
- Merger approved overwhelmingly: 35,119,793 votes for versus 32,508 against
- Transaction approval clears the primary shareholder condition for Parent’s acquisition of Avanos
Item 7.01: Regulation FD Disclosure
- Stockholders approved and adopted the Merger Agreement at the Special Meeting
- Approved merger transactions can proceed toward closing, subject to remaining conditions
Item EX-99.1: Item EX-99.1
- Stockholders approved AIP’s acquisition with 99.75% of voted shares supporting the transaction
- Approval represented 74.96% of total outstanding shares as of June 18, 2026
Item 8.01: Other Events
- Merger remains scheduled for July 22, 2026, with the board continuing its unanimous recommendation for the $25.00-per-share transaction
- Two lawsuits seek to enjoin the merger, while stockholder demand letters allege proxy disclosure deficiencies
AI summaries of AVNS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AVNS
Don't miss the next AVNS filing
- Alerts as it files. A push when AVNS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AVNS, by share count.
- Ask anything. An AI agent that reads every AVNS filing and answers with sources.
AVNS alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Galovan Scott Michael | A | Jul 27, 2026 | 96,121 | - |
| Galovan Scott Michael | D | Jul 27, 2026 | 69,630 | - |
| Delgado Sigfrido | D | Jul 27, 2026 | 21,914 | - |
| Galovan Scott Michael | D | Jul 27, 2026 | 135,596 | $25.00 |
| Delgado Sigfrido | A | Jul 27, 2026 | 54,886 | - |
| Galovan Scott Michael | D | Jul 27, 2026 | 96,121 | $25.00 |
| Delgado Sigfrido | D | Jul 27, 2026 | 55,741 | $25.00 |
| Delgado Sigfrido | D | Jul 27, 2026 | 37,520 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $687.8M | $701.2M |
| Gross Profit | $379.7M | $381.3M | $353.9M |
| Operating Income | - | -$396.2M | -$61.6M |
| Net Income | -$61.8M | -$392.1M | -$72.9M |
| Gross Margin | - | 55.4% | 50.5% |
| Op. Margin | - | -57.6% | -8.8% |
| Net Margin | - | -57.0% | -10.4% |
| Balance Sheet | |||
| Total Assets | $1.7B | $1.2B | $1.1B |
| Equity | - | $828.5M | $778.2M |
| ROE | - | -47.3% | -9.4% |
| Per Share | |||
| EPS | $-1.32 | $-8.53 | $-1.57 |
| Cash Flow | |||
| Operating CF | - | $100.7M | $74.7M |
Source: XBRL data in AVANOS MEDICAL, INC. (AVNS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate AVNS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 29 | $480.1M |
| Q1 2026 | 29 | $284.7M |
| Q4 2025 | 28 | $248.3M |
| Q3 2025 | 28 | $271.5M |
| Q2 2025 | 28 | $269.7M |
| Q1 2025 | 24 | $225.3M |
| Q4 2024 | 21 | $235.0M |
| Q3 2024 | 21 | $234.5M |
- Millennium Management+1.51M (+10927%)
- JPMorgan Chase & Co+848.6K (+338%)
- BlackRock+625.1K (+9%)
- Goldman Sachs Group+284.5K (+59%)
- Bank of America Corp+75.0K (+68%)
- Dimensional Fund Advisors−2.04M (-99%)
- AQR Capital Management−579.7K (-84%)
- Ameriprise Financial−503.7K (-86%)
- D.E. Shaw & Co−390.7K (-58%)
- Morgan Stanley−355.0K (-43%)
- Citadel Advisors LLC−475.2K
- Marex Group plc−25.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 208 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AVNS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| SC 13G | Jul 31, 2026 | - | - | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 8-K | Jul 22, 2026 | - | Analysis | - |
| 8-K | Jul 15, 2026 | - | Analysis | - |
| 8-K | Jul 2, 2026 | - | Analysis | - |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 4 | Apr 24, 2026 | - | - | - |
| 4 | Apr 24, 2026 | - | - | - |
| 4 | Apr 16, 2026 | - | - | - |
| 8-K | Apr 14, 2026 | - | Analysis | - |
| 4 | Apr 1, 2026 | - | - | - |
Related Health Care companies
- ALGN · Align TechnologyOrthopedic, Prosthetic & Surgical Appliances & Supplies
- AVR · Anteris Technologies Global Corp.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- EW · Edwards LifesciencesOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ENOV · Enovis CORPOrthopedic, Prosthetic & Surgical Appliances & Supplies
- INGN · Inogen IncOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ISRG · Intuitive SurgicalOrthopedic, Prosthetic & Surgical Appliances & Supplies
- LAKE · LAKELAND INDUSTRIES INCOrthopedic, Prosthetic & Surgical Appliances & Supplies
- MYO · MYOMO, INC.Orthopedic, Prosthetic & Surgical Appliances & Supplies
AVNS SEC filings: frequently asked questions
Which institutions hold AVNS stock?
As of June 30, 2026, the largest AVANOS MEDICAL, INC. (AVNS) holders among the 13F filers tracked by SignalX were BlackRock ($185.8 million), State Street Corp ($50.0 million), Vanguard Capital Management LLC ($49.6 million), Millennium Management ($37.9 million), JPMorgan Chase & Co ($27.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AVNS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), AVANOS MEDICAL, INC. (AVNS) reported revenue of $701.2 million (up 1.9% from FY2024) and a net loss of $72.9 million. Diluted EPS was -$1.57. The figures come from the XBRL data in the 10-K.
What did AVNS report in its latest 8-K?
AVANOS MEDICAL, INC. (AVNS) filed an 8-K on July 30, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 3.03 (Material Modification to Rights of Security Holders), Item 7.01 (Regulation FD Disclosure) and Item 5.01 (Changes in Control of Registrant). Legacy June 24, 2022 credit agreement fully repaid and terminated at merger closing.
What are the latest AVNS SEC filings?
AVANOS MEDICAL, INC. (AVNS) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on May 5, 2026, an 8-K current report on July 30, 2026 and a Form 4 insider filing on July 28, 2026.
What is AVNS's SEC CIK number?
AVANOS MEDICAL, INC. (AVNS)'s SEC Central Index Key (CIK) is 1606498. EDGAR lists every AVNS filing under that number.
Ask anything about AVNS
The research agent reads AVNS's filings, financials, insider trades and 13F holders, then answers with sources.